Barbosa-Breda J:青光眼的临床代谢组学研究综述!

2017-09-04 cuiguizhong MedSci原创

近日Barbosa-Breda J在Barbosa-Breda J杂志上发表了一篇综述,系统的介绍了目前对青光眼代谢组学的研究。

近日Barbosa-Breda J在Barbosa-Breda J杂志上发表了一篇综述,系统的介绍了目前对青光眼代谢组学的研究。

青光眼是目前全球不可逆致人失明的主要原因之一。然而,到目前为止,还没有可以准确帮助临床医师进行早期诊断或检测高风险的人群的生物标志物。代谢组学是对生物体中所有代谢物的研究,并且具有提供生物标志物的潜力。

作者在本综述中总结了科研人员对青光眼患者代谢组学的研究,并对这一领域的发展前景进行展望。他们研究重点集中在已发表的代谢组学和眼科学相关的文献。在对眼科代谢组学进行概述之后,他们集中精力讨论了人类青光眼的研究进展。在青光眼患者中总共进行了5项研究,并且将患者与健康对照者进行了比较。他们发现, 通过质谱法分析,血浆中涉及棕榈酰肉碱、鞘脂、维生素D相关化合物和类固醇前体的代谢途径在青光眼和健康者之间存在显着差异。核磁共振波谱实验发现,谷氨酰胺 - 谷氨酸与肌酸的比率在玻璃体和外侧膝状体中显着升高。在视辐射中没有检测到显着差异,在geniculocalcarine和条纹区观察到较低的N-乙酰天冬氨酸/胆碱比值。代谢组学可以将青光眼护理深入到个体化治疗,并促进人们对青光眼病理生理学新的认识。这项工作为眼科临床医生提供了新的治疗选择。

原文出处:

Barbosa-Breda, J., et al., Clinical Metabolomics and Glaucoma. Ophthalmic Res, 2017.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804789, encodeId=abd41804e890e, content=<a href='/topic/show?id=c4bee764836' target=_blank style='color:#2F92EE;'>#组学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77648, encryptionId=c4bee764836, topicName=组学研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Feb 17 10:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242563, encodeId=26b8242563e5, content=也许代谢组学可以更多的应用在临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Sun Sep 10 15:34:14 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349758, encodeId=3bcc1349e58ce, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480278, encodeId=2c7714802e800, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240432, encodeId=d9692404325b, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:46 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2018-02-17 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804789, encodeId=abd41804e890e, content=<a href='/topic/show?id=c4bee764836' target=_blank style='color:#2F92EE;'>#组学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77648, encryptionId=c4bee764836, topicName=组学研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Feb 17 10:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242563, encodeId=26b8242563e5, content=也许代谢组学可以更多的应用在临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Sun Sep 10 15:34:14 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349758, encodeId=3bcc1349e58ce, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480278, encodeId=2c7714802e800, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240432, encodeId=d9692404325b, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:46 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-10 1531f1a381m

    也许代谢组学可以更多的应用在临床

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1804789, encodeId=abd41804e890e, content=<a href='/topic/show?id=c4bee764836' target=_blank style='color:#2F92EE;'>#组学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77648, encryptionId=c4bee764836, topicName=组学研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Feb 17 10:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242563, encodeId=26b8242563e5, content=也许代谢组学可以更多的应用在临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Sun Sep 10 15:34:14 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349758, encodeId=3bcc1349e58ce, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480278, encodeId=2c7714802e800, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240432, encodeId=d9692404325b, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:46 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-06 bioon3
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804789, encodeId=abd41804e890e, content=<a href='/topic/show?id=c4bee764836' target=_blank style='color:#2F92EE;'>#组学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77648, encryptionId=c4bee764836, topicName=组学研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Feb 17 10:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242563, encodeId=26b8242563e5, content=也许代谢组学可以更多的应用在临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Sun Sep 10 15:34:14 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349758, encodeId=3bcc1349e58ce, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480278, encodeId=2c7714802e800, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240432, encodeId=d9692404325b, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:46 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804789, encodeId=abd41804e890e, content=<a href='/topic/show?id=c4bee764836' target=_blank style='color:#2F92EE;'>#组学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77648, encryptionId=c4bee764836, topicName=组学研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Feb 17 10:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242563, encodeId=26b8242563e5, content=也许代谢组学可以更多的应用在临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Sun Sep 10 15:34:14 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349758, encodeId=3bcc1349e58ce, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480278, encodeId=2c7714802e800, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Sep 06 08:15:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240432, encodeId=d9692404325b, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:46 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-04 131****1460

    学习了受益匪浅.

    0

相关威廉亚洲官网

Nanoscale.:具有持续药物释放能力的聚(ε-己内酯)纳米载体:用于长期青光眼治疗!

台湾桃园长庚大学生物化学与生物医学工程研究所的Lee CH, 近日在Nanoscale 杂志上发表了一项有趣的工作,标题为"Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment",他们开发持续和长期释放青光眼药物毛果芸香碱

Exp Parasitol.:两种商业性常用于降低眼压的眼药水具有抗棘阿米巴原虫活性!

西班牙拉古纳大学热带病与公共卫生大学研究所的Sifaoui I近日在Exp Parasitol杂志上发表了一项有趣的工作,标题为"Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure."他们发现有两种常用于降低眼压的眼药水具有抗棘阿米巴

我国基于MRI的改良视神经蛛网膜下腔间隙垂直截面积测量方法专家共识(2017年)

现有的基于MRI视神经蛛网膜下腔间隙垂直截面积测量方法尚有需要改进之处一,(1)所用MRI序列扫描时问过长;(2)不能准确标定所得平面到视神经起始位置的距离;(3)视神经个体差异大,并不是单一的标准圆形,尤其在视网膜神经节细胞死亡及视神经轴突丢失的疾病中,视神经截面形状更多样化,因而用直径来检测视神经的解剖状态并不精确。若在获得准确、清晰图像的基础上获得视神经周围蛛网膜下腔间隙的面积,将对临床工作

Expert Rev Ophthalmol:BDNF/TrkB信号通路在视觉系统中的作用:对青光眼的治疗意义!

美国奥古斯塔大学眼科系的Bollinger KE教授近日在Korean J Ophthalmol杂志上发表了一篇综述,系统的阐述了BDNF / TrkB信号通路在青光眼发展过程的作用,并对其治疗提出展望。

J Glaucoma.:纤维血管生长引起Ahmed Valve上游阻塞的手术解决方法!

葡萄牙圣玛丽亚医院眼科系的Medeiros Pinto J近日在J Glaucoma杂志上发表了一篇文章,他们介绍了一例年轻的患者,在穿透性角膜移植术后患有晚期青光眼和慢性葡萄膜炎,并进行探索实验,成功通过手术方法来治疗纤维血管生长引起Ahmed Valve上游阻塞。

Nat Genet:12 万人基因测序找到预防青光眼的突变基因

青光眼作为当今全球不可逆失明的主要原因,深深的困扰着许多人。近日,一项迄今为止规模最大的青光眼国际研究合作有可能为治疗和预防青光眼指明了方向。这项涉及全世界 6 大洲 36 个国家 12 万多人的研究,用深度基因测序的方法,发现了一种可以预防青光眼的突变基因。这项研究结果最近发表在《自然》子刊《Nature Genetics》期刊上。